Correction of increased prostacyclin synthesis in Bartter's syndrome by indometracin treatment

H. G. Gullner, J. B. Smith, C. Cerletti, J. R. Gill, F. C. Bartter

Research output: Contribution to journal › Article

Abstract

The role of prostacyclin and thromboxane A2 in the pathogenesis of Bartter's syndrome was investigated by measurement of the urinary excretion of 6-keto-PGF1α and thromboxane B2, respectively, in five patients. The prostaglandin metaeolites were extracted from urine by a reproducible method and measured by specific radioimmunoassays. The patients with Bartter's syndrome excreted about four-times as much 6-keto-PGF1α as the normal controls.In contrast, there was no significant difference in the urinary excretion of thromboxane B2 between the patients and the controls. In a second part of the study, three patients were treated with indomethacin (150 mg/day for four days), an inhibitor of prostaglandin synthesis. This regimen suppressed urinary excretion of 6-keto-PGF by 437 and that of thromboxane B2 by 467. It is suggested that the increase in prostacyclin production is responsible for both the hyperreninemia and the other endocrine derangements as well as the hyporesponsiveness of blood pressure to intravenous infusion of vasopressors in patients with Bartter's syndrome.

Original languageEnglish
Pages (from-to)65-72
Number of pages8
JournalProstaglandines and Medicine
Volume4
Issue number2
DOIs
Publication statusPublished - 1980

Fingerprint

Bartter Syndrome
Epoprostenol
Thromboxane B2
Therapeutics
Prostaglandin Antagonists
Thromboxane A2
Prostaglandins F
Intravenous Infusions
Indomethacin
Prostaglandins
Radioimmunoassay
Urine
Blood Pressure

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Correction of increased prostacyclin synthesis in Bartter's syndrome by indometracin treatment. / Gullner, H. G.; Smith, J. B.; Cerletti, C.; Gill, J. R.; Bartter, F. C.

In: Prostaglandines and Medicine, Vol. 4, No. 2, 1980, p. 65-72.

Research output: Contribution to journal › Article

Gullner, HG, Smith, JB, Cerletti, C, Gill, JR & Bartter, FC 1980, 'Correction of increased prostacyclin synthesis in Bartter's syndrome by indometracin treatment', Prostaglandines and Medicine, vol. 4, no. 2, pp. 65-72. https://doi.org/10.1016/0161-4630(80)90036-1
Gullner HG, Smith JB, Cerletti C, Gill JR, Bartter FC. Correction of increased prostacyclin synthesis in Bartter's syndrome by indometracin treatment. Prostaglandines and Medicine. 1980;4(2):65-72. https://doi.org/10.1016/0161-4630(80)90036-1
Gullner, H. G. ; Smith, J. B. ; Cerletti, C. ; Gill, J. R. ; Bartter, F. C. / Correction of increased prostacyclin synthesis in Bartter's syndrome by indometracin treatment. In: Prostaglandines and Medicine. 1980 ; Vol. 4, No. 2. pp. 65-72.
@article{4f4a3bb84bad47488ecb588af246ce5e,
title = "Correction of increased prostacyclin synthesis in Bartter's syndrome by indometracin treatment",
abstract = "The role of prostacyclin and thromboxane A2 in the pathogenesis of Bartter's syndrome was investigated by measurement of the urinary excretion of 6-keto-PGF1α and thromboxane B2, respectively, in five patients. The prostaglandin metaeolites were extracted from urine by a reproducible method and measured by specific radioimmunoassays. The patients with Bartter's syndrome excreted about four-times as much 6-keto-PGF1α as the normal controls.In contrast, there was no significant difference in the urinary excretion of thromboxane B2 between the patients and the controls. In a second part of the study, three patients were treated with indomethacin (150 mg/day for four days), an inhibitor of prostaglandin synthesis. This regimen suppressed urinary excretion of 6-keto-PGF by 437 and that of thromboxane B2 by 467. It is suggested that the increase in prostacyclin production is responsible for both the hyperreninemia and the other endocrine derangements as well as the hyporesponsiveness of blood pressure to intravenous infusion of vasopressors in patients with Bartter's syndrome.",
author = "Gullner, {H. G.} and Smith, {J. B.} and C. Cerletti and Gill, {J. R.} and Bartter, {F. C.}",
year = "1980",
doi = "10.1016/0161-4630(80)90036-1",
language = "English",
volume = "4",
pages = "65--72",
journal = "Prostaglandins and Medicine",
issn = "0161-4630",
publisher = "Churchill Livingstone",
number = "2",

}

TY - JOUR

T1 - Correction of increased prostacyclin synthesis in Bartter's syndrome by indometracin treatment

AU - Gullner, H. G.

AU - Smith, J. B.

AU - Cerletti, C.

AU - Gill, J. R.

AU - Bartter, F. C.

PY - 1980

Y1 - 1980

N2 - The role of prostacyclin and thromboxane A2 in the pathogenesis of Bartter's syndrome was investigated by measurement of the urinary excretion of 6-keto-PGF1α and thromboxane B2, respectively, in five patients. The prostaglandin metaeolites were extracted from urine by a reproducible method and measured by specific radioimmunoassays. The patients with Bartter's syndrome excreted about four-times as much 6-keto-PGF1α as the normal controls.In contrast, there was no significant difference in the urinary excretion of thromboxane B2 between the patients and the controls. In a second part of the study, three patients were treated with indomethacin (150 mg/day for four days), an inhibitor of prostaglandin synthesis. This regimen suppressed urinary excretion of 6-keto-PGF by 437 and that of thromboxane B2 by 467. It is suggested that the increase in prostacyclin production is responsible for both the hyperreninemia and the other endocrine derangements as well as the hyporesponsiveness of blood pressure to intravenous infusion of vasopressors in patients with Bartter's syndrome.

AB - The role of prostacyclin and thromboxane A2 in the pathogenesis of Bartter's syndrome was investigated by measurement of the urinary excretion of 6-keto-PGF1α and thromboxane B2, respectively, in five patients. The prostaglandin metaeolites were extracted from urine by a reproducible method and measured by specific radioimmunoassays. The patients with Bartter's syndrome excreted about four-times as much 6-keto-PGF1α as the normal controls.In contrast, there was no significant difference in the urinary excretion of thromboxane B2 between the patients and the controls. In a second part of the study, three patients were treated with indomethacin (150 mg/day for four days), an inhibitor of prostaglandin synthesis. This regimen suppressed urinary excretion of 6-keto-PGF by 437 and that of thromboxane B2 by 467. It is suggested that the increase in prostacyclin production is responsible for both the hyperreninemia and the other endocrine derangements as well as the hyporesponsiveness of blood pressure to intravenous infusion of vasopressors in patients with Bartter's syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0018916953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018916953&partnerID=8YFLogxK

U2 - 10.1016/0161-4630(80)90036-1

DO - 10.1016/0161-4630(80)90036-1

M3 - Article

C2 - 6994153

AN - SCOPUS:0018916953

VL - 4

SP - 65

EP - 72

JO - Prostaglandins and Medicine

JF - Prostaglandins and Medicine

SN - 0161-4630

IS - 2

ER -

Access to Document